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Abstract  
 
Objective: To identify predictors of epilepsy and clinical relapses in children presenting with ADEM  
Methods: Children presenting with ADEM between 2005 and 2017 and tested clinically for MOG-Ab, 
were identified from three tertiary paediatric neurology centres in the UK. Patients were followed-up for 
a median of 6years (range 1-16 years). 
Results:  74 children were studied (38 females; median age at first presentation: 4.5 years (range: 1.4– 
16). MOG-Ab was positive in 50/74(67.6%) of cases, and 27(54%) of MOG-Ab positive children 
presented with a neurological relapse over time. MOG-Ab was more frequently positive in the relapsing 
group than in the monophasic  group (27/31 vs 23/43; odds ratio 5.9(95% CI 1.8-19.7); p=0.002). 
16/74(22%) children had seizures during the acute presentation with ADEM and 12/74(16.2%) patients 
were diagnosed with post-ADEM epilepsy. The diagnosis of post-ADEM epilepsy was more frequently 
observed in children with relapsing disease than monophasic disease (10/31 vs 2/43; odds ratio 9.8 
(95% CI: 2.0-48.7); p=0.003), positive intrathecal oligoclonal bands than those with negative bands (4/7 
vs 4/30; odds ratio 8.7(95% CI: 1.4-54.0); p=0.027) and positive MOG-Ab than negative MOG-Ab cases 
(11/12 vs 39/62; odds ratio 6.5(95% CI:0.8-53.6); p=0.051).  
Conclusion: A higher relapse rate and a greater risk of  post-ADEM epilepsy in children with MOG-Ab-
associated disease may indicate a chronic disease with immune-mediate seizures in these children.  
 
 4 
Introduction   1 
Acute disseminated encephalomyelitis (ADEM) is an immune-mediated demyelinating CNS disorder 2 
most frequently presenting in younger children1. Patients present with polyfocal neurological deficits 3 
associated with encephalopathy, often accompanied by fever and a systemic illness. MRI typically 4 
demonstrates reversible, ill-defined white matter lesions of the brain and often also the spinal cord1. 5 
Although a favorable outcome is commonly reported, a proportion of affected children will present with 6 
clinical relapses over time. Predicting children who will have an isolated episode of demyelination and 7 
good recovery, or have subsequent relapses and neurological sequelae may help both in the 8 
counselling of parents, and potentially the tailoring of medical management to an inidividual’s risk. 9 
 10 
It has  been long recognised that children with ADEM may relapse with more than one clinical 11 
syndrome.  Based on multiple long-term surveillance study of children with acquired demyelinating 12 
syndromes (ADS), relapses following ADEM as  defined by the International Paediatric Multiple 13 
Sclerosis Study Group (IPMSSG) revised criteria2  may occur with patients having a (i) recurrence of 14 
neurological symptoms within 3 months, often as immunomodulatory treatment is being weaned, and 15 
now defined as the same ADEM episode; (ii) second episode of ADEM after 3 months defined as 16 
“multiphasic” where there is either re-emergence of previous neurologic symptoms or new and different 17 
signs and magnetic resonance imaging (MRI) findings; or (iii) second clinical event is not associated 18 
with encephalopathy, occurs three or more months after the incident neurologic event, and is 19 
associated with revised radiologic McDonald 2010 criteria for dissemination in space, thus meeting the 20 
criteria for multiple sclerosis (MS)3 21 
 22 
The clinical phenotypes of children with MOG-Ab associated disease include monophasic ADEM4, 23 
ADEM followed by recurrent optic neuritis (ON)5, or AQP4-negative NMOSD6. MOG-Ab are present in 24 
more than 30% of children who present with an initial episode of demyelination7, in more than 50% of 25 
those presenting with ADEM8, and in almost all those with multiphasic ADEM (MDEM)9. Although 26 
initially thought to be associated with predominantly white matter disease, there are increasing reports 27 
of both adults10, 11 and children12 with MOG-Ab-associated disease presenting with grey matter disease 28 
and seizures. Recent report of isolated seizures (in the absence of ADEM) during the first episode of 29 
relapsing MOG-Ab associated demyelination in children, suggested that MOG-Ab may be a cause of an 30 
autoimmune epilepsy13 31 
 32 
The objective of this study was to identify clinical features and investigations that predict clinical 33 
relapses and post-ADEM epilepsy. Furthermore, we examined the electro-encephalograms (EEG) of 34 
those children with post-ADEM epilepsy to obtain insights into the pathological processes that may 35 
contribute to the ongoing morbidity. 36 
 37 
 5 
 1 
 2 
Methods 3 
All children (under the age of 18yrs)  were diagnosed with ADEM at first presentation with an acquired 4 
demyelinating syndrome between 2005-2017 and were tested for MOG-Ab during the course of their 5 
disease. This is a subgroup of a larger cohort of acquired demyelinating syndrome including patients 6 
from the Evelina Children’s Hospital, Great Ormond Street Children’s Hospital, and Birmingham 7 
Children’s Hospital, previously described8.  8 
 9 
All patients were tested in Oxford for both MOG-Ab and AQP4-Ab (using live cell-based assays, as 10 
previously described)7 as part of routine clinical care, but not always at the time of first presentation.   11 
We defined an incident cohort comprising those patients who developed symptoms after January 2014 12 
(when MOG-Ab test was clinically available and tested during the acute presentation) and a 13 
retrospective cohort of children presenting before 2014 in whom the antibody testing was done 14 
retrospectively (either at time of relapse or from a sample previously sent for AQP4-Ab testing). All 15 
patients were managed according to their clinical diagnosis and the patients’ antibody status did not 16 
impact treatment decisions.  17 
 18 
Demographic information, clinical features at presentation, discharge and follow-up, and results of 19 
laboratory investigations, neuroimaging and EEG were compiled. EEGs were performed in accordance 20 
with national guidelines (30min for  awake EEG and 60min for sleep).Demyelinating phenotype at onset 21 
was determined from the patient’s clinical features, according to established criteria14. A relapse was 22 
defined as an acute or subacute episode of new or increasing neurological dysfunction followed by a full 23 
or partial recovery, in the absence of fever or infection.15 Relapsing cases were assigned the following 24 
diagnostic categories: (1) ADEM, if the relapses only occurred within 3 months from symptoms onset (2) 25 
MDEM fulfilling the 2013 IPMSSG consensus criteria2 (3)ADEM-ON defined as ADEM or recurrent 26 
ADEM proceeded with episodes of ON5  (4)NMOSD, fulfilling the 2015 Wingerchuk criteria for antibody 27 
negative.16 Further neurological events were defined as either a relapse, or the development of post-28 
ADEM epilepsy, or both.  29 
   30 
Post-ADEM epilepsy was defined as seizures requiring treatment with one or more anti-epileptic drugs 31 
(AEDs) for two or more years after the initial episode of ADEM, adopted from the definition of post-32 
encephalitis epilepsy.17 Drug resistant epilepsy was defined as failure of adequate trials of two tolerated, 33 
appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or in 34 
combination) to achieve sustained seizure freedom18. Children with a recognisable epilepsy syndrome 35 
were excluded from either a diagnosis of post-ADEM epilepsy or DRE.  For those children who went on 36 
 6 
to develop post-ADEM epilepsy, all EEGs performed beyond the acute period (more than one month 1 
from presentation or relapse) were reviewed by an epileptologist.  2 
 3 
 4 
Statistical analysis  5 
Statistical analysis was performed using the commercially available software SPSS Version 24 (IBM, 6 
CA). Nonparametric statistical tests (Mann-Whitney tests) were used for continuous distributions, and 7 
χ2 or Fisher exact tests were used for nominal data when comparing groups (relapsing versus 8 
monophasic; post-ADEM epilepsy versus no post-ADEM epilepsy and incident cohort versus 9 
retrospective cohort). Fisher exact test was used when any field had a value <5. 10 
Multivariate binary logistic regression utilising potential predictors at disease onset that achieved a 11 
univariate significance of <0.1 was used to calculate odds ratios and 95% confidence intervals for 12 
predictors of post-ADEM epilepsy and  relapsing disease. Statistical significance was taken at 0.05.   13 
 14 
Ethical approval  15 
This study was approved by Great Ormond Street Hospital Research and Development Department 16 
(reference 16NC10) 17 
 7 
Results 1 
Seventy-four patients (38 females and 36 males; median age at first presentation: 4.5 years (range: 2 
1.4– 16)) fulfilled the clinical criteria for ADEM at first presentation14 and were included in this study. 3 
Brain MRI at onset was abnormal in all children and in keeping with a diagnosis of ADEM. Cerebro-4 
spinal fluid (CSF) microscopy was available in 49 children, of whom 16 (21.6%) had raised white cell 5 
count (>5x106); CSF protein was elevated (>0.45g/dl) in 10/46 (13.5%) children, and oligoclonal bands 6 
were positive in 8/37 children (21.6%).   7 
 8 
MOG-Ab was positive in 50/74 (67.6%) of ADEM cases. AQP4-Ab was negative in all patients.  9 
 10 
16/74 (22%) children had seizures during the acute presentation of ADEM, and 12/74 (16.2%) patients 11 
were diagnosed with post-ADEM epilepsy. None of the patients were diagnosed with drug resistant 12 
epilepsy.  13 
 14 
 15 
As we were concerned about introducing bias when comparing the clinical and paraclinical features of 16 
children in whom MOG-Ab testing was done during the first presentation (n=25) with those in whom it 17 
was performed retrospectively (n=49). We confirmed there were no differences in any of the clinical 18 
features at presentation (supplemental table 1). Despite the longer follow-up time in the retrospective 19 
cohort we did not detect a difference in the rate of relapse (p=0.084)  and post-ADEM epilepsy 20 
(p=0.203)  21 
 22 
Relapsing disease 23 
Patients were followed-up for a median of 6 years (range 1-16); 43/74 (58.1%) had monophasic 24 
disease, while 31 (41.9%) went on to have a subsequent relapse. 27/31 were MOG-Ab positive. The 25 
final diagnosis was ADEM (n=46), MDEM (n=19), ADEM-ON (n=3) and NMOSD (n=6). None of the 26 
children were diagnosed with multiple sclerosis. Ten patients relapsed within three months of diseases 27 
onset, of which 3 children had only a single relapse. Of those three children one was MOG-Ab positive, 28 
and two MOG-Ab negative.  Figure 1 shows the frequency of relapse events. One child who was MOG-29 
Ab negative had 2 clinical relapses. All 11 children who had more than 2 relapses were MOG-Ab 30 
positive(Figure 1a). Survival without relapse is presented in Figure 1b, demonstrating a higher 31 
probability of relapse free survival in those who are MOG-Ab negative (Mantel-Cox p=0.04).  32 
 33 
The presence of MOG-Ab gave an odds ratio of subsequent relapse of 5.9 (95% CI: 1.8-19.7)(p=0.002). 34 
Post-ADEM epilepsy was associated with an increased risk of subsequent relapse (odds ratio 9.8 (95% 35 
CI: 2.0-48.7)(p=0.003)(Table 1) 36 
 37 
 8 
As potential early predictors of subsequent relapse, presence of MOG-Ab and seizures at presentation 1 
were entered into a multivariate binary regression mode. Only the presence of MOG-Ab remained a 2 
significant predictor of subsequent relapse (odds ratio 5.4 (95% CI:1.6-18.4); p=0.007). 3 
 4 
Post-ADEM epilepsy  5 
Twelve (16.2%) children (4 females and 8 males; median age at presentation: 5.5 years (range: 2.6 -6 
9.2); median duration of follow-up 8.5 years (range: 3-17 years)) developed post-ADEM epilepsy. Six of 7 
the 12 developed seizures at first presentation. The median time to onset of seizures was 3 months 8 
(range 0-61 months), with four children having seizures that continued from first presentation. MOG-Ab 9 
was positive in 11/12 (91.7%) children with post-ADEM epilepsy.  10 
 11 
All patients with post-ADEM epilepsy were treated with at least one anti-epileptic drug two years after 12 
presentation. The decision to treat, duration of treatment and choise of AED were based on clinical and 13 
EEG findings (and not antibody positivity).  One child had complete seizure control on two anti-epileptic 14 
drugs. All patients remained on AEDs two years from the acute presentation.   15 
Ten (83.3%) children with post-ADEM epilepsy went on to have a relapsing disease course.  The final 16 
diagnosis for children with post-ADEM epilepsy was MDEM (n=6), NMOSD (n=2), ADEM (n=2), and 17 
ADEM-ON (n=2). 18 
 19 
The clinical characteristics of these children in comparison to children who did not develop epilepsy are 20 
presented in Table 2. Neuroimaging and EEG findings of the 12 children who went on to develop post-21 
ADEM epilepsy were reviewed. EEG outside of the acute presentation in those children with a diagnosis 22 
of post-ADEM epilepsy showed focal or generalized slowing, and in one case an excess of fast activity 23 
(secondary to medication). The clinical history and characteristics are summarized in Table 3. 24 
 25 
Children with seizures at first presentation were more likely to develop post-ADEM epilepsy. The odds 26 
ratio of developing post-ADEM epilepsy with seizures at first presentation was 5.2 (95% CI 1.4-19.4; 27 
p=0.009). There was a greater risk of post-ADEM epilepsy in children who relapsed than those who did 28 
not (odds ratio 9.8 (95% CI: 2.0-48.7); p=0.001), had positive oligoclonal bands than those who did not 29 
(odds ratio 8.7 (95% CI: 1.4-54.0); p=0.027), and a trend towards a greater risk in those who were 30 
MOG-Ab positive than those who were MOG-Ab negative (odds ratio 6.5 (95% CI: 0.8-53.6); p=0.051). 31 
(Table 2) 32 
 33 
When seizures occurred at onset, MOG-Ab positivity and positive OCB were entered into a multivariate 34 
binary logistic regression model, both the presence of oligoclonal bands in the CSF (odds ratio 20.7 35 
(95% CI: 1.5-286); p=0.023) and seizures at onset (odds ratio 13.5 (95%CI:1.1-171); p=0.044) 36 
remained significant predictors of post-ADEM epilepsy. 37 
 9 
 1 
Discussion 2 
In this study we have demonstrated that there is a greater risk of relapse in children presenting with 3 
ADEM who are MOG-Ab positive. While in our cohort relapse was seen in MOG-Ab negative patients, 4 
none went on to have more than two clinical relapses in contrast to several MOG-Ab positive patients 5 
who went on to have up to 20 relapses. This suggests that in the absence of MOG-Ab the risk of long 6 
term relapsing disease is relatively small, which may play a role in targeting immune modulation 7 
therapy. 8 
 9 
Our results are  in keeping with a previous finding of MOG-Ab identified in 19/33(57%) of children with 10 
ADEM.4 In that study 4/19 (21%) children with MOG-Ab developed multiphasic disease compared to 11 
0/14 of the MOG-Ab negative group. In our study we report multiphasic disease in 54% of children 12 
positive for MOG-Ab. The higher relapse rate in our cohort may reflect the longer duration of follow-up 13 
(median 6 years versus median 2 years) and indeed a longer duration of follow-up was associated with 14 
an increasing likelihood of further neurological morbidity. Although we did not detect a difference in the 15 
rate of relapse between the incident and retrospective cohort, there was a trend towards a higher rate of 16 
relapsing disease in the retrospective cohort which may have contributed to this.  Twenty seven out of 17 
31 children who relapsed had MOG-Ab; all 27 patients matched the typical phenotype thought to 18 
correspond with MOG-Ab positivity19. The other four children who were MOG-Ab negative and relapsed 19 
all had an MDEM phenotype. The only difference detected between the MOG-Ab positive vs MOG-Ab 20 
negative relapsing cases was the total number of relapses (Figure 2) 21 
 22 
AQP4-Ab was negative in all patients. The patients who were diagnosed with NMOSD fulfilled the IPMD 23 
2015 criteria20 (which stratify patients into AQP4-Ab positive and negative). Nevertheless, although 24 
these patients fulfilled the criteria, the MOG-Ab positive children had a distinct phenotype to children 25 
reported with AQP4-Ab NMOSD21. In a large cohort of 197 adult patients with MOG-Ab22 only 19% of 26 
patients fulfilled the IPND 2015 criteria for NMOSD. This emphasizes the complexity of classifying 27 
patients based on the clinical instead of biological phenotype 28 
 29 
The second important observation of this study is that in the 12/74 that developed post ADEM-epilepsy, 30 
seizures at presentation and OCB  positivity were early predictive risk factors. Seizures have been 31 
reported in other acquired demyelinating syndromes. The incidence of epilepsy is higher in adults with 32 
multiple sclerosis compared to the general population, with the increased risk resulting from a high risk 33 
in those with progressive disease.23 The authors hypothesise that an increased grey matter lesion 34 
burden in progressive disease may account for the increased incidence of epilepsy.  Although seizures 35 
are frequently reported during acute presentation with ADEM1, in a single center Australian cohort of 34 36 
 10 
children with ADEM  there were no reports of post-ADEM seizures despite using the same diagnostic 1 
criteria.17  2 
 3 
The association of intrathecal OCBs at presentation with the development of post-ADEM epilepsy may 4 
support the hypothesis that post-ADEM epilepsy may result from chronic inflammation. As the CSF 5 
analysis for oligoclonal bands were performed in only 37 patients, the small sample size and the lack of 6 
longitudinal assessment of CSF (which was not done clinically for children with ADEM) limits the clinical 7 
utility of these findings. In adults with NMDA-receptor encephalopathy mild clinical relapses with 8 
seizures may be related to subtle rises in CSF antibody titres not reflected in serum titres.24  The 9 
relationship between MOG-Ab titres and clinical disease activity remains an area of active investigation, 10 
however the  utility and applicability of this remains to be evaluated clinically in light of challenges of 11 
measuring antibody titres beyond a research setting. As the patients reported in this cohort were tested 12 
clinically, it was not possible to determine if deterioration in seizure control was associated with 13 
fluctuation in MOG-Ab titres.   14 
 15 
There are strengths and limitations to this study. We have captured all children with a diagnosis of 16 
ADEM in whom MOG-Ab was tested from three tertiary paediatric neurology centres as previously 17 
described.8 MOG-Ab testing was introduced clinically as of January 2014. Therefore this study includes 18 
both children whose serum was retrospectively tested, and those tested at presentation as part of 19 
clinical assessment. This introduces a potential for selection bias in that those children with a relapsing 20 
or more severe disease course may be more likely to be tested retrospectively. There may therefore be 21 
an over representation of children with relapsing disease who go on to be tested for MOG-Ab in the 22 
retrospective cohort.  Furthermore, patients were recruited from specialised neuroimmunology centers 23 
and it is therefore possible that we have overrepresentation  in our cohort of a more severe phenotype.  24 
 25 
The proportion of children with a final diagnosis of ADEM was inevitably higher in the prospective 26 
cohort, in whom follow-up duration was shorter but interestingly there were no differences in the rate of 27 
relapse and the risk of post ADEM epilepsy. MRI analysis in those under 6 years of age typically 28 
requires general anaesthesia, and thus one of the obvious limitations of this study is the lack of 29 
standardised imaging, at regular follow-up times or at time of seizures to assess for evidence of disease 30 
accrual. Furthermore, imaging analysis focusing on grey matter involvement may help distinguish 31 
chronic inflammation from gliotic scaring as the cause of post-ADEM epilepsy.  32 
 33 
To examine the relative significance of predictors of relapse or post-ADEM epilepsy we have 34 
undertaken multivariable logistic regression. This is limited by the small numbers in both the relapsing 35 
group, and the post-ADEM epilepsy group, which increases the risk of clinically significant predictors not 36 
achieving statistical significance. Furthermore, data was acquired clinically and not all parameters (for 37 
 11 
example oligoclonal band results) were available for all patients. Similarly, as all EEG were performed 1 
clinically, differences exist across different centres. Often, in accommodating the less compliant child, a 2 
shorter and imcomplete recording epoch is inevitable. These results must therefore be interpreted with 3 
the greatest caution. 4 
 5 
This study is the first to identify an association between MOG-Ab associated disease and post-ADEM 6 
epilepsy in children. Although post-ADEM epilepsy could result from synaptic reorganisation or 7 
perturbation resulting from inflammation, the finding on EEG in those with post-ADEM epilepsy of focal 8 
or generalized slowing often discordant to epileptiform discharges, suggest that the possibility of a 9 
persisting low grade brain dysfunction mediated by inflammation cannot be discounted 10 
 11 
In conclusion, in this study we demonstrate a higher relapse rate in children with MOG-Ab-associated 12 
ADEM, and a trend towards a greater risk of post-ADEM epilepsy. We hypothesise that this may be a 13 
result of ongoing subclinical inflammation resulting in recurring seizures supported by the higher rate of 14 
intrathecal oligoclonal bands detected in these patients. MOG-Ab-associated disease may therefore 15 
reflect a true antibody-mediated epilepsy, and treatment of seizures in these children, particularly in 16 
those without epileptic discharges on EEG or focal scarring on MRI, may be best directed towards 17 
management of an ongoing inflammatory process.  18 
 19 
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Figure 1: Number of relapse events according to MOG-Ab status 
 
 
 
Figure 2: Kaplan-Meier plot showing relapse free survival according to MOG-Ab status. Diamonds 
(MOG-Ab negative) and lines (MOG-Ab positive) show the point at which relapse free patients were 
censored (last point of follow-up) 
 
 
 
Table 1: clinical and paraclinical features of monophasic and relapsing patients. (CSF – cerebrospinal 
fluid; WCC – white cell count; OCB – oligoclonal bands) 
 
Relapse 
(n=31) 
Monophasic disease 
(n=43) 
Odds ratio 
(95%CI) 
p-value 
 
Sex (F:M) 18:13 20:23 0.7 (0.3-1.7) 0.355 
Age at presentation 
(months) 
47 (20-157) 67 (17-178) 
 
0.191 
Prodrome present 17/26 28/34 0.4 (0.1-1.3) 0.148 
Raised CSF WCC 8/22 8/27 1.4 (0.4-4.5) 0.761 
Raised CSF protein 7/22 3/24 3.3 (0.7-14.7) 0.159 
CSF OCB 6/21 2/16 2.8 (0.5-16.2) 0.423 
MOG-Ab 27/31 23/43 5.9 (1.8-19.7) 0.002 
Seizures at 
presentation 
10/31 6/43 
2.9 (0.9-9.2) 
0.086 
Seizures post-ADEM 10/31 2/43 9.8 (2.0-48.7) 0.003 
Duration of follow-up 
from first 
presentation (years) 
7 (1-16) 5 (2-7) 
 
0.001 
 
 
 
 
Table 2: Clinical characteristics according to development of post-ADEM epilepsy 
 
Post-ADEM 
seizures 
(n=12) 
No post-ADEM 
seizures 
(n=62) 
Odds ratio 
(95% CI) 
p-value 
 
Sex (F:M) 4:8 34:28 2.4 (0.7-8.9) 0.172 
Age at presentation 
(months) 
66 (31-110) 53 (17-178) 
 
0.558 
Prodrome present 7/11 38/49 0.5 (0.1-2.0) 0.335 
Raised CSF WCC 4/8 12/41 
2.4 (0.5-
11.3) 
0.411 
Raised CSF protein 3/7 7/39 
3.4 (0.6-
18.9) 
0.163 
CSF OCB 4/7 4/30 
8.7 (1.4-
54.0) 
0.027 
MOG-Ab 11/12 39/62 
6.5 (0.8-
53.6) 
0.051 
Seizures at presentation 6/12 10/62 
5.2 (1.4-
19.4) 
0.009 
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Relapse 10/12 20/62 
9.8 (2.0-
48.7) 
0.001 
Final diagnosis     
ADEM 2/12 44/62  <0.001 
MDEM 6/12 13/62  0.035 
NMOSD 2/12 4/62  0.249 
ADEM-ON 2/12 1/62  0.067 
Duration of follow-up 
from first presentation 
(years) 
8 (3-17) 5 (1-12) 
 
<0.001 
 
 17 
Table 3: Clinical history and characteristics of the 12 children who developed post-ADEM epilepsy 
  Demogr
aphics 
Diagnosis 
at last 
follow-up 
Clinical presentation MOG-Ab 
status 
Subsequent neurologic events Seizure semiology Time to 
onset of 
seizures 
(Months) 
Initial and/or latest interictal EEG 
 
MRI pattern AED Maintenance 
Immunotherapy 
Outcome and comorbidities 
1 
 
9yr M 
Mixed  
ADEM Encephalopathy, 
behavioural change 
and focal 
neurological signs 
Negative  Nil Focal seizures onset 
from one year 
following ADEM 
11 Occasional bursts of sharp and slow activity 
and spike and wave discharges against a 
normal background.  During sleep left sided 
discharges appear more frequent.  
Compatible with an increased liability to 
focal seizures. 
Multifocal, hazy/poorly 
marginated lesions 
involving both the grey 
matter and white matter 
Topiramate  Nil Good seizure control for 2 
years; Left hemiplegia; Normal 
Cognition 
 
2 
 
14yr M 
Mixed  
ADEM-ON Vomiting, severe 
headache and 
confusion and optic 
neuritis. 
Positive Relapse with optic neuritis five years 
after first presentation 
Aura of nausea 
followed by twitching 
of arms or legs on 
either side lasting up 
to 2 minutes. 
60 Asymetrical background. Loss of posterior 
rhythms and improving  slowing over left 
hemisphere. No epileptiform discharges 
seen. 
Multifocal, hazy/poorly 
marginated lesions 
involving both the grey 
matter and white matter 
Carbamazepine 
 
Nil No further seizures; Normal 
neurology; Normal cognition 
3 
 
4yr F  
White 
British  
MDEM Behavioural change, 
ataxia and bilateral 
6th nerve palsy 
following a febrile 
illness 
Positive Multiple relapses at 9-12 month 
intervals characterised by altered 
behaviour, loss of balance, 
weakness (left more than right), and 
slurred speech over 10years 
 Left sided motor 
seizures 
4 Normal background rhythms. Persistent 
slow activity over the right hemisphere in 
keeping with a focal lesion. No epileptiform 
activity seen.  
Leukodystrophy-like  
 
Levetiracetam 
 
On Azathioprine for 
three years which was 
then discontinued. 
Continues to relapse 
yearly.  
On-going seizures,  
motor, cognitive and 
behavioural difficulties 
  
4 
 
6yr M 
White 
British 
ADEM-ON Encephalopathy with 
seizures.   
Intubated and 
ventilated for 7 days 
Positive Three episodes of ON (8, 9 and 10 
years from ADEM) 
Episodes of brief 
behavioural arrests. 
Developed soon 
after the initial 
presentation and 
PICU admission. 
Persisted for 9 
months, 
subsequently 
controlled with 
Sodium Valproate   
0 At presentation: Diffuse slowing. No periodic 
or epileptiform activity seen 
6 months follow-up: Focal slowing with no 
epileptiform discharge 
Cortical encephalitis  Previously 
Sodium 
Valproate  
Nil  Seizure free off treatment; 
Normal neurology; Moderate 
learning difficulties; Significant 
anxiety disorder. 
5 
 
3yr M 
Indian  
MDEM Encephalopathy, 
ataxia and ON  
Positive Multiple relapses at 6-12month 
intervals characterised by altered 
behaviour, loss of balance, 
weakness (left more than right), and 
slurred speech over 10years 
Eye deviation to the 
left, with right sided 
facial twitching and 
impaired 
consciousness.   
48 Excess fast activity with 1-2Hz slow waves 
in left posterior region. Definite assymetry. 
Focal encephalopathy. Sharpened 
morphology left parietal left temporal, right 
sided sharp over P3, C4. Non-specific sharp 
waves, scatted sharps.  
Leukodystrophy-like  
 
Levetiracetam Managed with Beta-
interferon with no 
change in relapse 
frequency.  
Seizure breakthrough with 
intercurrent illness; Normal 
neurology; Cognitive and 
behaviour difficulties 
6 
 
3yr F 
Black 
African 
NMOSD Encephalopathy, 
slurred speech and 
ataxia. Persistent 
left-sided squint.  
Positive One relapse at 6yr with simultaneous 
left ON+LETM  
Prolonged focal 
dyscognitive seizure. 
8 First EEG- Widespread high amplitude 
slowing. Few focal spikes.  
9 month EEG - generalised 3Hz spike and 
wave. 7/11 intermittent slow waves, 
intermittent sharp transients. 12/2012   
disorganised cerebral activity. Nothing 
epileptiform. 
Leukodystrophy-like  
 
Levetiracetam Nil Yearly breakthrough seizure; 
Normal neurology; No cognitive 
problems 
7 
 
2yr M 
Kuwait 
MDEM Encephalopathy, 
seizures, pyrexia, 
lower limb weakness, 
vomiting and 
lethargy. 
Positive At 1year, encephalopathy, seizures 
and cerebellar signs 
Episodes of eye 
flickering, lip 
smacking and right 
sided tonic-clonic 
seizures.  
0 Normal  Cortical encephalitis  Oxcarbazepine Nil 2-3 seizures monthly; Normal 
neurology; Cognitive and 
behavioural difficulties 
8 
 
4yr F 
Caucas
ian  
MDEM Encephalopathy, 
lethargy and an 
unsteady gait. 
Positive Recurrent relapses with lethargy, 
ataxia, slurred speech and rigidity 
associated with increased seizure 
frequency.  
Prolonged 
generalised tonic 
clonic seizure (1.5 
years after first 
demyelination). 
Ongoing focal 
seizures 
 
 
18 Abnormal excess of slow activity, more 
prominent slowing over left hemisphere. No 
discharges 
Multifocal, hazy/poorly 
marginated lesions 
involving both the grey 
matter and white matter 
Lamotrigine Managed with Beta-
interferon with no 
change in relapse 
frequency. 
Yearly left sided focal seizures; 
Subtle cerebellar signs; Mild 
learning difficulties.  
9 
 
8yr M 
White 
British 
MDEM Encephalopathy, 
seizures and 
headaches.  
Intubated and 
ventilated for 3days  
Positive A further ADEM like presentation 7 
years after initial presentation with 
encephalopathy and seizures.  
Generalised tonic-
clonic seizures from 
presentation.  
0 1-2Hz - slow waves more in right frontal and 
left temporal region. Encephalopathic. 
PLEDS right frontotemporal and left 
centrotemporal on left 
Cortical encephalitis  
 
Sodium 
Valproate  
Nil  GTCS twice a year; Normal 
neurology; Behavioural 
problems 
10 
 
8yr M 
White 
other  
NMOSD Encephalopathy,  
neck stiffness, 
headache, optic 
neuritis and urinary 
incontinence.   
Positive Multiple relapses with 
encephalopathy, seizures, ataxia and 
optic neuritis 
From presentation 
he developed right 
focal motor seizures 
with secondary 
generalisation.  
0 Slowing right frontotemporal and posteriorly. 
No discharges. 
Multifocal, hazy/poorly 
marginated lesions 
involving both the grey 
matter and white matter 
Lamotrigine, 
oxcarbazepine 
Continued to relapse on 
Interferon, Rituximab 
and Natalizumab. 
Relapse free on 
monthly IVIG 
On-going seizures often 
accompanying intercurrent 
illness; Dysarthria, dysmetria, 
impaired right eye vision; Mild 
cognitive difficulties 
11 
 
6yr M 
White 
British  
ADEM Encephalopathy, 
ataxia and 6th nerve 
palsy. 
Positive N/A Focal seizure from 3 
months after 
presentation. Well 
controlled on 
Topiramate. Last 
3 Assymetrical background with reduction of 
amplitude of posterior rhythms over the left 
hemisphere. No epileptiform discharges 
Multifocal, hazy/poorly 
marginated lesions 
involving both the grey 
matter and white matter 
Topiramate  Nil  No seizures; Normal neurology 
Normal cognition and 
behaviour  
 18 
seizure 2 years after 
presentation 
12 
 
5yr F 
White 
British 
MDEM Encephalopathy, 
ataxia and right focal 
seizures  
 
Positive Nine months after initial presentation 
developed encephalopathy with 
seizure and ataxia with new changes 
on imaging. Also developed optic 
neuritis. Nine or ten relapses over a 
six year period with longest inter-
attack period of two years. 
 
Right -sided focal 
motor seizure.  
0 Background abnormality with excess of slow 
activity. Not focal, no epileptiform features 
 
Leukodystrophy-like  Keppra 
Carbamazepine 
Continued to relapse on 
Azathioprine and 
interferone. Stable on 
Natulizimab 
2 seizures a month; Normal 
neurology; Cognitive and 
attention difficulties.  
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